Tandem Diabetes Care, Inc. (TNDM)
NASDAQ: TNDM · Real-Time Price · USD
23.45
+0.47 (2.05%)
At close: May 12, 2025, 4:00 PM
23.95
+0.50 (2.13%)
After-hours: May 12, 2025, 7:37 PM EDT
Tandem Diabetes Care Revenue
Tandem Diabetes Care had revenue of $234.42M in the quarter ending March 31, 2025, with 22.30% growth. This brings the company's revenue in the last twelve months to $982.95M, up 27.65% year-over-year. In the year 2024, Tandem Diabetes Care had annual revenue of $940.20M with 25.74% growth.
Revenue (ttm)
$982.95M
Revenue Growth
+27.65%
P/S Ratio
1.57
Revenue / Employee
$370,925
Employees
2,650
Market Cap
1.56B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 940.20M | 192.49M | 25.74% |
Dec 31, 2023 | 747.72M | -53.50M | -6.68% |
Dec 31, 2022 | 801.22M | 98.42M | 14.00% |
Dec 31, 2021 | 702.80M | 203.97M | 40.89% |
Dec 31, 2020 | 498.83M | 136.53M | 37.68% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
TNDM News
- 6 days ago - Tandem Diabetes Care Announces Upcoming Conference Presentations - Business Wire
- 12 days ago - Tandem Diabetes Care, Inc. (TNDM) Q1 2025 Earnings Conference Call Transcript - Seeking Alpha
- 12 days ago - Tandem Diabetes Care Announces First Quarter 2025 Financial Results - Business Wire
- 5 weeks ago - Tandem Diabetes Care to Announce First Quarter 2025 Financial Results on April 30, 2025 - Business Wire
- 7 weeks ago - Tandem Diabetes Care Announces NEJM Publication of Positive Pivotal Study Outcomes with Control-IQ+ AID Technology in Type 2 Diabetes - Business Wire
- 7 weeks ago - Tandem Diabetes Care Launches New Control-IQ+ Automated Insulin Delivery Technology in the United States - Business Wire
- 2 months ago - Tandem Diabetes Q4 Earnings Review: I Don't Share The Market's Skepticism - Seeking Alpha
- 2 months ago - Tandem Diabetes Care, Inc. (TNDM) Q4 2024 Earnings Call Transcript - Seeking Alpha